Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies

Value Health. 2019 Aug;22(8):970-971. doi: 10.1016/j.jval.2018.12.013. Epub 2019 May 25.

Authors

Marric Buessing¹, Thomas O'Connell¹, Scott Johnson¹, Sarah Pitluck², Thomas A Ciulla²

Affiliations

¹ Medicus Economics, Boston, MA, USA.
² Spark Therapeutics, Philadelphia, PA, USA.

PMID: 31426938
DOI: 10.1016/j.jval.2018.12.013

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cost-Benefit Analysis
Drug Costs
Genetic Therapy
Humans
Retinal Diseases*
United States
United States Food and Drug Administration